Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 12Other hematologic neoplasm 11Lymphoid 11Breast 9Other solid neoplasm 7Dermatologic 7Thoracic 5Sarcoma 4Head & Neck 4Plasma cell 3Myeloid 3Gynecologic 3CNS 3Tumor-Agnostic 1Genitourinary 1Endocrine 1Classical hematology 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pharmacogenomic Testing × Tumor-Agnostic × Clear all
NCT06744712 2026-03-25

Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients

Wake Forest University Health Sciences

Phase NA Not yet recruiting
130 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡